Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics, Inc., listed on Nasdaq under the symbol VYGR, is a pioneering gene therapy company dedicated to developing transformative treatments for severe neurological diseases. Founded in 2014 by leaders in the fields of AAV gene therapy and neuroscience, Voyager focuses on conditions like Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich's ataxia. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary TRACER™ AAV capsid discovery platform to create gene therapies with high efficacy and broad brain penetration.
The company’s gene therapy platform, TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA), allows for the engineering, optimization, and delivery of AAV-based therapies. This platform has enabled the discovery of novel capsids that exhibit enhanced penetration of the blood-brain barrier and targeted delivery to central nervous system (CNS) tissues.
Voyager's pipeline includes several promising programs. The most advanced is the anti-tau antibody VY-TAU01, aimed at treating Alzheimer’s disease and expected to generate key tau PET imaging data by 2026. Other pipeline projects include gene therapies targeting SOD1 for ALS, and FXN gene therapy for Friedreich’s ataxia.
Financially, Voyager maintains a robust balance sheet. As of December 31, 2023, Voyager reported approximately $431 million in pro-forma cash. This financial strength supports the company’s ongoing clinical trials and the advancement of its gene therapy programs. Voyager collaborates with several industry leaders, including Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc. These partnerships provide additional resources and expertise to accelerate the development and commercialization of its therapeutic candidates.
Voyager's achievements have garnered attention within the biotechnology industry. The company's commitment to innovation and the development of life-changing treatments makes it a significant player in the field of gene therapy.
For the latest updates, financial results, and news about Voyager Therapeutics, visit their website at www.voyagertherapeutics.com.
Voyager Therapeutics (VYGR) has selected VY1706 as its lead development candidate for tau silencing gene therapy in Alzheimer's disease. The company plans to file IND and CTA applications in 2026. VY1706 combines siRNA technology to reduce tau expression with an IV-delivered TRACER capsid that can penetrate the blood-brain barrier. In non-human primate studies, a single VY1706 dose achieved 50% to 73% reduction in tau mRNA levels across the cerebral cortex, particularly in areas where tau accumulates during Alzheimer's progression. This marks the fifth neuro gene therapy development candidate using Voyager's TRACER capsids.
Voyager Therapeutics (VYGR) reported Q3 2024 financial results with collaboration revenue of $24.6 million, up from $4.6 million in Q3 2023. Net loss decreased to $9.0 million from $25.9 million year-over-year. The company completed enrollment in its VY7523 anti-tau antibody trial for Alzheimer's, with top-line data expected H1 2025. Voyager secured a new $15 million upfront payment from Novartis for a TRACER capsid license and received a $3 million milestone payment from Neurocrine. Cash position stands at $345.4 million, providing runway into 2027.
Voyager Therapeutics (VYGR) has announced its participation in four upcoming investor conferences in November 2024. The company will be present at the Truist Securities BioPharma Symposium in New York City (Nov 7), the Guggenheim Inaugural Healthcare Innovation Conference in Boston (Nov 13), the B. Riley Securities' Next-Gen Tissue Delivery Modalities Virtual Summit (Nov 14), and the Stifel 2024 Healthcare Conference in New York City (Nov 18).
Webcasts will be available for select conferences and can be accessed through Voyager's investor relations website, with replays available for at least 30 days.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast through the company's investor relations website, with a replay available for at least 30 days after the event.
Voyager Therapeutics (Nasdaq: VYGR) has announced the selection of a third gene therapy development candidate in collaboration with Neurocrine Biosciences. This candidate, targeting an undisclosed neurological disease, utilizes Voyager's TRACER™ capsid discovery platform for intravenous administration and blood-brain barrier penetration.
The selection triggers a $3 million milestone payment to Voyager, expected in Q4 2024. This follows previous nominations for Friedreich's ataxia and GBA1 Parkinson's disease. Voyager is eligible for additional development and commercialization milestone payments, plus royalties on potential future sales.
The collaboration, established in 2023, covers multiple neurological programs. For each undisclosed program, Voyager can receive up to $175 million in development milestones, commercial milestone payments, and tiered royalties on global net sales.
Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabled gene therapies to 14 programs.
Key financial terms include:
- $15 million upfront payment to Voyager
- Up to $305 million in potential milestone payments
- Tiered mid- to high-single digit royalties on potential products
This marks the fifth gene therapy program in collaboration with Novartis, including Huntington's disease, spinal muscular atrophy, and three undisclosed indications.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has granted inducement awards to a new employee. The awards, approved by the Compensation Committee under Nasdaq Rule 5635(c)(4), include:
1. A non-qualified stock option for 40,000 shares of common stock, effective August 28, 2024, with a ten-year term and an exercise price of $6.49 per share. It vests over four years: 25% after one year, then 75% monthly over three years.
2. Restricted stock units for 20,000 shares, effective October 1, 2024, vesting annually in equal installments over three years.
Both awards are subject to continued employment and specific award agreements.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in two upcoming investor conferences in September 2024:
- The Wells Fargo 2024 Healthcare Conference in Boston, with a fireside chat on September 5 at 1:30 p.m. ET
- The Baird 2024 Global Healthcare Conference in New York City, featuring a fireside chat on September 11 at 1:25 p.m. ET
Webcasts of the presentations will be available on the Investors section of Voyager's website and archived for at least 30 days. This announcement highlights Voyager's engagement with investors and its commitment to sharing updates on its progress in the field of neurogenetic medicine.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The company will engage in a fireside chat on August 14, 2024, at 9:30 a.m. ET.
Investors and interested parties can access a webcast of the presentation through the Investors section of Voyager's website at ir.voyagertherapeutics.com. For those unable to attend live, a replay of the webcast will be available on the company's website for a minimum of 30 days following the event.
Voyager Therapeutics (Nasdaq: VYGR) reported its Q2 2024 financial results and operational progress. Key highlights include:
1. Initiated Phase 1a single ascending dose trial of anti-tau antibody VY7523 for Alzheimer's disease, with top-line data expected in H1 2025.
2. Advanced three CNS gene therapy programs towards INDs in 2025.
3. Appointed Nathan Jorgensen, Ph.D., as CFO.
4. Strong cash position of $371 million as of June 30, 2024, providing runway into 2027.
5. Q2 2024 collaboration revenue increased to $29.6 million, up from $4.9 million in Q2 2023.
6. Net loss decreased to $10.1 million in Q2 2024, compared to $22.2 million in Q2 2023.
7. R&D expenses increased to $34.5 million in Q2 2024, up from $22.0 million in Q2 2023.
FAQ
What is the current stock price of Voyager Therapeutics (VYGR)?
What is the market cap of Voyager Therapeutics (VYGR)?
What is Voyager Therapeutics’ primary focus?
What is the TRACER™ platform?
Where is Voyager Therapeutics headquartered?
What are some key programs in Voyager’s pipeline?
Who are some of Voyager’s strategic partners?
What is the financial condition of Voyager Therapeutics?
When was Voyager Therapeutics founded?
What is the significance of VY-TAU01?
How does Voyager’s TRACER platform contribute to their therapies?
Where can I find more information about Voyager Therapeutics?
